PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS
申请人:F. Hoffmann-La Roche AG
公开号:EP1868999A1
公开(公告)日:2007-12-26
US7229999B2
申请人:——
公开号:US7229999B2
公开(公告)日:2007-06-12
[EN] PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS<br/>[FR] DERIVES DE PYRIDINE-3-CARBOXAMIDE UTILISES COMME AGONISTES INVERSES DES CB1
申请人:HOFFMANN LA ROCHE
公开号:WO2006106054A1
公开(公告)日:2006-10-12
[EN] The present invention relates to compounds of the formula (I) wherein X and R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity. [FR] L'invention concerne des composés de formule (I) dans laquelle X et R1 à R8 sont tels que définis dans la description et les revendications et des sels de ceux-ci acceptables sur le plan pharmaceutique. Les composés sont utiles dans le traitement et/ou la prophylaxie de maladies associées à la modulation des récepteurs CB1, telle que l'obésité.
Pyridine-3-carboxamide derivatives as CB1 inverse agonists
申请人:Hebeisen Paul
公开号:US20060229326A1
公开(公告)日:2006-10-12
The present invention relates to compounds of the formula
wherein X and R
1
to R
8
are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.